Galectin Therapeutics (GALT) Long-Term Debt Issuances (2021)
Galectin Therapeutics (GALT) posted quarterly Long-Term Debt Issuances of $10.0 million for Q4 2021, little changed quarter-over-quarter from $10.0 million in Q3 2021.
Powered by 
Analysis
Galectin Therapeutics (GALT) Long-Term Debt Issuances (2021) Analysis & Trends
Galectin Therapeutics' Long-Term Debt Issuances history runs 1 years deep, the most recent figure standing at $10.0 million for Q4 2021.
- In Q4 2021, Long-Term Debt Issuances changed N/A year-over-year to $10.0 million; the TTM figure through Dec 2022 stood at $20.0 million (changed N/A YoY), while the FY2021 annual figure was $30.0 million, changed N/A from the prior year.
- Long-Term Debt Issuances for Q4 2021 stood at $10.0 million, roughly flat from $10.0 million in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $10.0 million in Q3 2021, with the low at $10.0 million in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Galectin Therapeutics | 304.34 Mn | 304.34 Mn | - | - |